Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of $ K_{v} $1.3 potassium channels, AKT and ERK1/2 signaling
Background Treatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxicity. Promising new therapeutic targets in cancer therapy include voltage-gated $ K_{v} $1.3 potassium channels, but their role in acute leukemia is unclear. We reported that $ K_{v} $1.3 channels of lymphocytes are blocked by memantine, which is known as an antagonist of neuronal N-methyl-D-aspartate type glutamate receptors and clinically applied in therapy of advanced Alzheimer disease. Here we evaluated whether pharmacological targeting of $ K_{v} $1.3 channels by memantine promotes cell death of acute leukemia cells induced by chemotherapeutic cytarabine. Methods We analyzed acute lymphoid (Jurkat, CEM) and myeloid (HL-60, Molm-13, OCI-AML-3) leukemia cell lines and patients’ acute leukemic blasts after treatment with either drug alone or the combination of cytarabine and memantine. Patch-clamp analysis was performed to evaluate inhibition of $ K_{v} $1.3 channels and membrane depolarization by memantine. Cell death was determined with propidium iodide, Annexin V and SYTOX staining and cytochrome C release assay. Molecular effects of memantine co-treatment on activation of Caspases, AKT, ERK1/2, and JNK signaling were analysed by Western blot. $ K_{v} $1.3 channel expression in Jurkat cells was downregulated by shRNA. Results Our study demonstrates that memantine inhibits $ K_{v} $1.3 channels of acute leukemia cells and in combination with cytarabine potentiates cell death of acute lymphoid and myeloid leukemia cell lines as well as primary leukemic blasts from acute leukemia patients. At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. In addition, it augments mitochondrial dysfunction resulting in enhanced cytochrome C release and activation of Caspase-9 and Caspase-3 leading to amplified apoptosis. Conclusions Our study underlines inhibition of $ K_{v} $1.3 channels as a therapeutic strategy in acute leukemia and proposes co-treatment with memantine, a licensed and safe drug, as a potential approach to promote cytarabine-based cell death of various subtypes of acute leukemia..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Cell communication and signaling - 17(2019), 1 vom: 16. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lowinus, Theresa [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s). 2019 |
|---|
| doi: |
10.1186/s12964-018-0317-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR028907884 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR028907884 | ||
| 003 | DE-627 | ||
| 005 | 20230519130328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12964-018-0317-z |2 doi | |
| 035 | |a (DE-627)SPR028907884 | ||
| 035 | |a (SPR)s12964-018-0317-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lowinus, Theresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of $ K_{v} $1.3 potassium channels, AKT and ERK1/2 signaling |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2019 | ||
| 520 | |a Background Treatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxicity. Promising new therapeutic targets in cancer therapy include voltage-gated $ K_{v} $1.3 potassium channels, but their role in acute leukemia is unclear. We reported that $ K_{v} $1.3 channels of lymphocytes are blocked by memantine, which is known as an antagonist of neuronal N-methyl-D-aspartate type glutamate receptors and clinically applied in therapy of advanced Alzheimer disease. Here we evaluated whether pharmacological targeting of $ K_{v} $1.3 channels by memantine promotes cell death of acute leukemia cells induced by chemotherapeutic cytarabine. Methods We analyzed acute lymphoid (Jurkat, CEM) and myeloid (HL-60, Molm-13, OCI-AML-3) leukemia cell lines and patients’ acute leukemic blasts after treatment with either drug alone or the combination of cytarabine and memantine. Patch-clamp analysis was performed to evaluate inhibition of $ K_{v} $1.3 channels and membrane depolarization by memantine. Cell death was determined with propidium iodide, Annexin V and SYTOX staining and cytochrome C release assay. Molecular effects of memantine co-treatment on activation of Caspases, AKT, ERK1/2, and JNK signaling were analysed by Western blot. $ K_{v} $1.3 channel expression in Jurkat cells was downregulated by shRNA. Results Our study demonstrates that memantine inhibits $ K_{v} $1.3 channels of acute leukemia cells and in combination with cytarabine potentiates cell death of acute lymphoid and myeloid leukemia cell lines as well as primary leukemic blasts from acute leukemia patients. At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. In addition, it augments mitochondrial dysfunction resulting in enhanced cytochrome C release and activation of Caspase-9 and Caspase-3 leading to amplified apoptosis. Conclusions Our study underlines inhibition of $ K_{v} $1.3 channels as a therapeutic strategy in acute leukemia and proposes co-treatment with memantine, a licensed and safe drug, as a potential approach to promote cytarabine-based cell death of various subtypes of acute leukemia. | ||
| 650 | 4 | |a Memantine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute leukemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cell death |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytarabine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Signaling |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Heidel, Florian H. |4 aut | |
| 700 | 1 | |a Bose, Tanima |4 aut | |
| 700 | 1 | |a Nimmagadda, Subbaiah Chary |4 aut | |
| 700 | 1 | |a Schnöder, Tina |4 aut | |
| 700 | 1 | |a Cammann, Clemens |4 aut | |
| 700 | 1 | |a Schmitz, Ingo |4 aut | |
| 700 | 1 | |a Seifert, Ulrike |4 aut | |
| 700 | 1 | |a Fischer, Thomas |4 aut | |
| 700 | 1 | |a Schraven, Burkhart |4 aut | |
| 700 | 1 | |a Bommhardt, Ursula |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell communication and signaling |d London : Biomed Central, 2003 |g 17(2019), 1 vom: 16. Jan. |w (DE-627)SPR028900014 |w (DE-600)2126315-2 |x 1478-811X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2019 |g number:1 |g day:16 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12964-018-0317-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2019 |e 1 |b 16 |c 01 | ||